Despite improvements in neuroblastoma treatment, survival figures lag behind those of many other childhood malignancies. New ...

Bayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide drugs for cancer as sales of its lead product in the category – Xofigo ...

She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted ...

AdvanCell is developing therapies to treat cancers including: prostate, skin, pancreatic, breast, bladder, colorectal, kidney ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...

Johnson Winter Slattery (JWS) has assisted three of the lead investors in AdvanCell’s US$112m Series C financing effort.

In connection with the release of the results for the full year and fourth quarter 2024, Oncoinvent invites to the following events: ...

This study utilizes bibliometric analysis to investigate the research landscape of FAP-directed cancer theranostics, focusing ...

AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, is expanding the scope and ...

AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an ...